Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Hilton Hotels Corporation Common Stock trades at $335.87 (market cap $76.37B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 92.4× Amphastar Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HLT | |
|---|---|---|
Market Cap | $826.08M | $76.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $350.22 |
52-Week Low | $16.87 | $256.75 |
Enterprise Value | $1.22B | $88.87B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Hilton Worldwide (HLT) trades at $335.48, down 0.64% on the day, with a bullish technical signal and strong earnings beat history. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though valuation multiples appear elevated with a P/E of 51.22. Recent news highlights brand campaigns and property renovations, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $342.11 implying modest upside. Risks include high debt levels and sensitivity to travel demand fluctuations. The stock offers growth exposure to hospitality recovery but requires monitoring of leverage and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
